Velpanat Tablet

Velpanat tablets may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.​

• Hepatitis B reactivation
  
• Severe allergic reactions
  
• Headache
  
• Dizziness
  
• Fatigue / Weakness
  
• Nausea
• Vomiting
• Insomnia (difficulty sleeping)
  
• Diarrhea
  
• Constipation
  
• Itching (pruritus)
  
• Decreased appetite
  
• Muscle or joint pain
  
• Rash
  
• Fever
  
• Anemia (low red blood cells)
  
• Neutropenia (low white blood cells)
  
• Breathing problems / Difficulty breathing
  
• Cough
  
• Bone pain
• Slow heart rate

• The Velapanat tablet is a combination of two antiviral medicines, such as Sofosbuvir and Velpatasvir.
•  It works by blocking the replication of the virus to reduce its levels in the body. 
• By suppressing viral replication, it helps to slow down the progression of liver damage and clear up the infection.
  

• Tests for hepatitis B before starting treatment to reduce the risk of HBV reactivation.

• Velpanat Tablet must not be combined with amiodarone, risking fatal bradycardia.

• May cause fatigue, dizziness, or blurred vision; avoid driving or tasks needing focus until you know how it affects you.

• Headaches are common; drink plenty of water and use a suitable painkiller; inform your doctor if they are persistent.

• Liver function and viral load should be monitored regularly during treatment.

• Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P., Gruener, N., … Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610.
  
• Feld et al. (2015). Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608–2617. https://doi.org/10.1056/NEJMoa1512612.
  
• Chandrashekhar et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. Hepatology International. https://doi.org/10.1007/s12072‑019‑09927‑6 Chang Gung Medical Foundation (2021). Effectiveness of sofosbuvir/velpatasvir in patients with advanced fibrosis or cirrhosis: a population-based study in Taiwan. Infectious Diseases and Therapy.
  
• Gaur, N. et al. (2019). Sofosbuvir–velpatasvir fixed-dose combination for treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. Journal of Clinical and Experimental Hepatology, 10(3), 189–193.
  
• Shah, V. et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in difficult-to-treat patients: A real-life observational study from India. Journal of Clinical and Experimental Hepatology.